These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37831471)

  • 1. Donanemab: Not two without a third.
    Kurkinen M
    Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
    JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donanemab in Early Alzheimer's Disease.
    Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
    N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
    Terao I; Kodama W
    Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Ebell MH; Barry HC; Baduni K; Grasso G
    Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
    Ross EL; Weinberg MS; Arnold SE
    JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
    Høilund-Carlsen PF; Alavi A; Barrio JR; Castellani RJ; Costa T; Herrup K; Kepp KP; Neve RL; Perry G; Revheim ME; Robakis NK; Sensi SL; Vissel B
    Ageing Res Rev; 2024 Aug; 99():102348. PubMed ID: 38830549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
    Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
    Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
    Jin M; Noble JM
    eNeuro; 2024 Sep; 11(9):. PubMed ID: 39332901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Terao I; Kodama W
    J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
    Dickson SP; Wessels AM; Dowsett SA; Mallinckrodt C; Sparks JD; Chatterjee S; Hendrix S
    J Prev Alzheimers Dis; 2023; 10(3):595-599. PubMed ID: 37357301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Qiao Y; Gu J; Yu M; Chi Y; Ma Y
    CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
    Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
    JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How donanemab data address the coverage with evidence development questions.
    Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
    Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
    Høilund-Carlsen PF; Alavi A; Castellani RJ; Neve RL; Perry G; Revheim ME; Barrio JR
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
    Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
    J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.